Full Text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes progressive autonomy loss and need for care. This does not only affect patients themselves, but also the patients’ informal caregivers (CGs) in their health, personal and professional lives. The big efforts of this multi-center study were not only to evaluate the caregivers’ burden and to identify its predictors, but it also should provide a specific understanding of the needs of ALS patients’ CGs and fill the gap of knowledge on their personal and work lives. Using standardized questionnaires, primary data from patients and their main informal CGs (n = 249) were collected. Patients’ functional status and disease severity were evaluated using the Barthel Index, the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and the King’s Stages for ALS. The caregivers’ burden was recorded by the Zarit Burden Interview (ZBI). Comorbid anxiety and depression of caregivers were assessed by the Hospital Anxiety and Depression Scale. Additionally, the EuroQol Five Dimension Five Level Scale evaluated their health-related quality of life. The caregivers’ burden was high (mean ZBI = 26/88, 0 = no burden, ≥24 = highly burdened) and correlated with patients’ functional status (rp = −0.555, p < 0.001, n = 242). It was influenced by the CGs’ own mental health issues due to caregiving (+11.36, 95% CI [6.84; 15.87], p < 0.001), patients’ wheelchair dependency (+9.30, 95% CI [5.94; 12.66], p < 0.001) and was interrelated with the CGs’ depression (rp = 0.627, p < 0.001, n = 234), anxiety (rp = 0.550, p < 0.001, n = 234), and poorer physical condition (rp = −0.362, p < 0.001, n = 237). Moreover, female CGs showed symptoms of anxiety more often, which also correlated with the patients’ impairment in daily routine (rs = −0.280, p < 0.001, n = 169). As increasing disease severity, along with decreasing autonomy, was the main predictor of caregiver burden and showed to create relevant (negative) implications on CGs’ lives, patient care and supportive therapies should address this issue. Moreover, in order to preserve the mental and physical health of the CGs, new concepts of care have to focus on both, on not only patients but also their CGs and gender-associated specific issues. As caregiving in ALS also significantly influences the socioeconomic status by restrictions in CGs’ work lives and income, and the main reported needs being lack of psychological support and a high bureaucracy, the situation of CGs needs more attention. Apart from their own multi-disciplinary medical and psychological care, more support in care and patient management issues is required.

Details

Title
Informal Caregiving in Amyotrophic Lateral Sclerosis (ALS): A High Caregiver Burden and Drastic Consequences on Caregivers’ Lives
Author
Schischlevskij, Pavel 1 ; Cordts, Isabell 2 ; Günther, René 3 ; Stolte, Benjamin 4   VIAFID ORCID Logo  ; Zeller, Daniel 5 ; Schröter, Carsten 6 ; Weyen, Ute 7 ; Regensburger, Martin 8   VIAFID ORCID Logo  ; Wolf, Joachim 9 ; Schneider, Ilka 10 ; Hermann, Andreas 11   VIAFID ORCID Logo  ; Metelmann, Moritz 12 ; Kohl, Zacharias 13   VIAFID ORCID Logo  ; Linker, Ralf A 13 ; Koch, Jan Christoph 14 ; Stendel, Claudia 15 ; Müschen, Lars H 1 ; Osmanovic, Alma 1   VIAFID ORCID Logo  ; Binz, Camilla 1 ; Klopstock, Thomas 16 ; Dorst, Johannes 17 ; Ludolph, Albert C 18 ; Boentert, Matthias 19   VIAFID ORCID Logo  ; Hagenacker, Tim 4   VIAFID ORCID Logo  ; Deschauer, Marcus 2 ; Lingor, Paul 2   VIAFID ORCID Logo  ; Petri, Susanne 1 ; Schreiber-Katz, Olivia 1   VIAFID ORCID Logo 

 Department of Neurology, Hannover Medical School, 30625 Hannover, Germany; [email protected] (P.S.); [email protected] (L.H.M.); [email protected] (A.O.); [email protected] (C.B.); [email protected] (S.P.) 
 Department of Neurology, Klinikum Rechts der Isar, Technical University of Munich, 81675 Munich, Germany; [email protected] (I.C.); [email protected] (M.D.); [email protected] (P.L.) 
 Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany; [email protected]; German Center for Neurodegenerative Diseases (DZNE), 01307 Dresden, Germany 
 Department of Neurology, University Medicine Essen, 45147 Essen, Germany; [email protected] (B.S.); [email protected] (T.H.) 
 Department of Neurology, University of Würzburg, 97080 Würzburg, Germany; [email protected] 
 Hoher Meißner Clinic, Neurology, 37242 Bad Sooden-Allendorf, Germany; [email protected] 
 Department of Neurology, Ruhr-University Bochum, BG-Kliniken Bergmannsheil, 44789 Bochum, Germany; [email protected] 
 Department of Molecular Neurology, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany; [email protected] 
 Department of Neurology, Diakonissen Hospital Mannheim, 68163 Mannheim, Germany; [email protected] 
10  Department of Neurology, Martin-Luther University Halle/Saale, 06120 Halle, Germany; [email protected]; Department of Neurology, Klinikum Sankt Georg, 04129 Leipzig, Germany 
11  Translational Neurodegeneration Section “Albrecht-Kossel”, Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany; [email protected]; German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald, 18147 Rostock, Germany 
12  Department of Neurology, University Hospital Leipzig, 04103 Leipzig, Germany; [email protected] 
13  Department of Neurology, University of Regensburg, 93053 Regensburg, Germany; [email protected] (Z.K.); [email protected] (R.A.L.) 
14  Department of Neurology, University Medicine Göttingen, 37075 Göttingen, Germany; [email protected] 
15  Department of Neurology, Friedrich-Baur Institute, University Hospital, Ludwig Maximilian University of Munich, 80336 Munich, Germany; [email protected] (C.S.); [email protected] (T.K.); German Center for Neurodegenerative Diseases (DZNE), 80336 Munich, Germany 
16  Department of Neurology, Friedrich-Baur Institute, University Hospital, Ludwig Maximilian University of Munich, 80336 Munich, Germany; [email protected] (C.S.); [email protected] (T.K.); German Center for Neurodegenerative Diseases (DZNE), 80336 Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), 80336 Munich, Germany 
17  Department of Neurology, University of Ulm, 89081 Ulm, Germany; [email protected] (J.D.); [email protected] (A.C.L.) 
18  Department of Neurology, University of Ulm, 89081 Ulm, Germany; [email protected] (J.D.); [email protected] (A.C.L.); German Center for Neurodegenerative Diseases (DZNE), 89081 Ulm, Germany 
19  Department of Neurology, Institute of Translational Neurology, University Hospital Münster, 48149 Münster, Germany; [email protected]; Department of Medicine, UKM Marienhospital, 48565 Steinfurt, Germany 
First page
748
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
20763425
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2544612758
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.